DCT

1:26-cv-00978

Eli Lilly & Co v. Eugia Pharma Specialities Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00978, D. Del., 08/06/2026
  • Venue Allegations: Plaintiff alleges venue is proper in the District of Delaware because two defendants are Delaware entities and the other two are foreign corporations that may be sued in any judicial district.
  • Core Dispute: Plaintiff alleges that Defendants' filing of Abbreviated New Drug Applications (ANDAs) to market generic versions of Plaintiff's Mounjaro® and Zepbound® drug products constitutes an act of infringement of ten patents covering the active ingredient tirzepatide, its formulation, and methods of use.
  • Technical Context: The technology relates to tirzepatide, a dual GIP/GLP-1 receptor co-agonist for treating type 2 diabetes and obesity, part of a highly significant and lucrative class of metabolic drugs.
  • Key Procedural History: This is a Hatch-Waxman action filed in response to Defendants' Paragraph IV certifications asserting that Plaintiff's patents are invalid, unenforceable, or will not be infringed by the proposed generic products. The complaint states the action was filed within 45 days of receiving the first of Defendants' notice letters. All asserted patents are listed in the FDA's Orange Book for Mounjaro®, Zepbound®, or both.

Case Timeline

Date Event
2015-01-09 Priority Date for '780 Patent
2016-10-25 '780 Patent Issued
2018-06-22 Priority Date for '820, '623, '755, '756 Patents
2018-07-23 Priority Date for '987, '382, '758, '740 Patents
2022-05-13 FDA Approval for Mounjaro®
2022-06-14 '820 Patent Issued
2023-11-08 FDA Approval for Zepbound®
2024-03-05 '623 Patent Issued
2025-05-13 '987 Patent Issued
2025-07-01 '382 Patent Issued
2025-10-28 '755, '756, and '758 Patents Issued
2026-05-05 '740 Patent Issued
2026-05-19 '404 Patent Issued
2026-07-02 Date of Defendants' First Notice Letter
2026-07-06 Date of Defendants' Second Notice Letter
2026-07-06 Lilly Receives First Notice Letter
2026-07-08 Lilly Receives Second Notice Letter
2026-08-06 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,474,780 - "GIP and GLP-1 Co-agonist Compounds"

The Invention Explained

  • Problem Addressed: The patent addresses the need for effective treatments for diabetes mellitus, a chronic disorder characterized by hyperglycemia U.S. Patent No. 11,357,820, col. 1:11-15
  • The Patented Solution: The invention is a specific peptide compound, tirzepatide, that acts as a co-agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors Compl. ¶24 This dual-agonist mechanism is designed to improve glycemic control and treat related conditions like obesity U.S. Patent No. 11,357,820, col. 1:19-24 The '780 Patent specifically claims the chemical structure of this compound Compl. ¶58
  • Technical Importance: This co-agonist approach represented a novel mechanism for treating type 2 diabetes and obesity, offering potentially greater efficacy than single-agonist GLP-1 therapies U.S. Patent No. 12,295,987, col. 1:44-53

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶59 Compl. ¶60
  • Claim 1 covers:
    • A compound of a specific 39-amino acid sequence formula.
    • The formula includes specific amino acid substitutions (Aib at positions X1 and X2).
    • The lysine (K) at position 20 is chemically modified through conjugation with a specific fatty acid-linker moiety.
    • The amino acid at position X3 is Phe or 1-Nal.
    • The C-terminal amino acid is optionally amidated.
  • The complaint does not explicitly reserve the right to assert dependent claims but alleges infringement of "one or more claims" Compl. ¶60

U.S. Patent No. 11,357,820 - "GIP/GLP1 AGONIST COMPOSITIONS"

The Invention Explained

  • Problem Addressed: The patent background describes the need for pharmaceutical compositions of tirzepatide that provide acceptable stability (both shelf-life and in-use) while also ensuring an "acceptable patient injection site experience" '820 Patent, col. 1:21-25 '820 Patent, col. 3:5-8 The patent notes that certain common formulation agents, such as citrate, can be associated with "painful stinging at the injection site" '820 Patent, col. 3:12-14
  • The Patented Solution: The invention is a specific pharmaceutical formulation that combines tirzepatide with sodium chloride (NaCl) in a defined concentration range and dibasic sodium phosphate '820 Patent, abstract This combination is described as providing the desired stability and an acceptable patient experience, being approximately isotonic with body fluids '820 Patent, col. 3:20-25 '820 Patent, col. 3:45-52
  • Technical Importance: This invention provides a stable, patient-tolerable liquid formulation for a major therapeutic peptide, which is critical for its commercial viability as a subcutaneously injected drug product.

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶75 Compl. ¶76
  • Claim 1 covers:
    • A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof.
    • NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL.
    • Dibasic sodium phosphate.
  • The complaint does not explicitly reserve the right to assert dependent claims but alleges infringement of "one or more claims" Compl. ¶77

U.S. Patent No. 11,918,623 - "GIP/GLP1 Agonist Compositions"

  • Issued: March 5, 2024
  • Technology Synopsis: This patent claims a method of treating obesity by administering a pharmaceutical composition containing tirzepatide. The patent specifies concentration ranges for tirzepatide, dibasic sodium phosphate, NaCl, and optionally phenol Compl. ¶92 The technology provides a specific formulation and method for using tirzepatide to treat obesity.
  • Asserted Claims: At least independent claim 1 Compl. ¶92 Compl. ¶93
  • Accused Features: Defendants are accused of infringement because they seek approval for proposed labeling that "instructs and encourages treating obesity" by administering a composition that allegedly meets the claimed concentration parameters Compl. ¶93

U.S. Patent No. 12,295,987 - "Methods of Using a GIP/GLP1 Co-agonist for Diabetes"

  • Issued: May 13, 2025
  • Technology Synopsis: The patent claims a method of treating type 2 diabetes using a specific dose-titration regimen. The method involves administering a first dose of a GIP:GLP-1 peptide with a specific potency ratio, followed by second, third, and fourth doses over specified time periods, with the doses having a specific percentage relationship to each other Compl. ¶111
  • Asserted Claims: At least independent claim 1 Compl. ¶111 Compl. ¶112
  • Accused Features: Defendants' proposed labeling for their generic Mounjaro® product allegedly "instructs and encourages treating type 2 diabetes" using the patented dosing regimen Compl. ¶112

U.S. Patent No. 12,343,382 - "Methods of Using a GIP/GLP1 Co-agonist for Therapy"

  • Issued: July 1, 2025
  • Technology Synopsis: The patent claims methods for treating type 2 diabetes (claim 1) and improving weight management (claim 11). The methods involve administering an "escalation dose" of tirzepatide for at least two weeks, followed by a "maintenance dose," with specific dosages listed for each phase Compl. ¶130 Compl. ¶132
  • Asserted Claims: At least independent claims 1 and 11 Compl. ¶¶130-133
  • Accused Features: Defendants' proposed labeling for their generic products allegedly instructs and encourages the treatment of type 2 diabetes and weight management using the claimed escalation and maintenance dose regimens Compl. ¶131 Compl. ¶133

U.S. Patent No. 12,453,755 - "GIP/GLP1 Agonist Compositions"

  • Issued: October 28, 2025
  • Technology Synopsis: This patent covers a method of treating diabetes by administering a pharmaceutical composition of tirzepatide with specific concentration ranges for the active ingredient, dibasic sodium phosphate, NaCl, and optional phenol Compl. ¶153 This method-of-treatment patent protects a specific formulation used for a specific indication.
  • Asserted Claims: At least independent claim 1 Compl. ¶153 Compl. ¶154
  • Accused Features: Defendants' proposed labeling for their generic Mounjaro® product allegedly instructs and encourages treating diabetes by administering a composition that falls within the claimed formulation parameters Compl. ¶154

U.S. Patent No. 12,453,756 - "GIP/GLP1 Agonist Compositions"

  • Issued: October 28, 2025
  • Technology Synopsis: This patent claims a pharmaceutical composition comprising tirzepatide and a specific concentration range of NaCl, with a defined pH range Compl. ¶171 The invention protects a simplified formulation of tirzepatide.
  • Asserted Claims: At least independent claim 1 Compl. ¶171 Compl. ¶172
  • Accused Features: Defendants' proposed generic products are alleged to be pharmaceutical compositions that meet the claim's requirements for tirzepatide, NaCl concentration, and pH Compl. ¶172

U.S. Patent No. 12,453,758 - "Methods of Using a GIP/GLP1 Co-agonist for Diabetes"

  • Issued: October 28, 2025
  • Technology Synopsis: This patent claims a method for improving weight management using a specific dose-titration regimen involving four doses of a GIP:GLP-1 peptide with a defined potency ratio Compl. ¶188 The dosing schedule specifies the relative percentages of the first, second, and third doses compared to the fourth dose.
  • Asserted Claims: At least independent claim 1 Compl. ¶188 Compl. ¶189
  • Accused Features: Defendants' proposed labeling for their generic Zepbound® product allegedly instructs and encourages the patented dosing regimen for weight management Compl. ¶189

U.S. Patent No. 12,616,740 - "Methods of Using a GIP/GLP1 Co-agonist for Therapy"

  • Issued: May 5, 2026
  • Technology Synopsis: The patent claims methods for treating type 2 diabetes (claim 1) and obesity (claim 6) by administering tirzepatide in a specific once-weekly dose escalation regimen. The regimen starts with 2.5 mg for four weeks, increases by 2.5 mg increments, with each new dose administered for at least four weeks, until a maintenance dose of 5, 10, or 15 mg is reached Compl. ¶206 Compl. ¶208
  • Asserted Claims: At least independent claims 1 and 6 Compl. ¶¶206-209
  • Accused Features: Defendants' proposed labeling allegedly instructs and encourages the claimed once-weekly dose escalation regimen for treating both type 2 diabetes and obesity Compl. ¶207 Compl. ¶209

U.S. Patent No. 12,629,404 - "GIP/GLP1 Agonist Compositions"

  • Issued: May 19, 2026
  • Technology Synopsis: This patent claims a preservative-free pharmaceutical composition comprising tirzepatide, a specific concentration range of sodium chloride, and a specific pH range Compl. ¶229 The invention protects a specific formulation suitable for single-dose applications.
  • Asserted Claims: At least independent claim 1 Compl. ¶229 Compl. ¶230
  • Accused Features: Defendants' proposed generic products are alleged to be compositions that contain tirzepatide, NaCl, and a pH within the claimed ranges, and are free of preservative Compl. ¶230

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are Defendants' "Proposed ANDA Products" for which they submitted ANDA Nos. 221740, 221742, and 221741 to the FDA Compl. ¶1 These products are generic versions of Mounjaro® and Zepbound® Compl. ¶1

Functionality and Market Context

  • The Proposed ANDA Products contain tirzepatide as the active pharmaceutical ingredient Compl. ¶52 They are intended to be marketed as generic equivalents for improving glycemic control in patients with type 2 diabetes, reducing body weight, and treating obstructive sleep apnea, mirroring the indications for Lilly's branded products Compl. ¶1
  • The products are formulated as autoinjectors in 2.5 mg/0.5 mL and 5 mg/0.5 mL strengths, and as single-dose vials in the same strengths Compl. ¶1 Compl. ¶11 The complaint alleges these products will be marketed as direct competitors to Mounjaro® and Zepbound® upon FDA approval Compl. ¶1 The complaint includes a chemical structure diagram of tirzepatide, the active ingredient in the accused products Compl. ¶59

IV. Analysis of Infringement Allegations

Infringement Allegations: U.S. Patent No. 9,474,780

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A compound of Formula: YX1EGTFTSDYSIX2LDKIAQKAX3VQWLIAGGPSSGAPPPS...or a pharmaceutically acceptable salt thereof. Defendants' Proposed ANDA Products contain tirzepatide, which the complaint alleges is a compound with the structural formula corresponding to the claim. ¶58; ¶59 '987 Patent, col. 37:45-53

Infringement Allegations: U.S. Patent No. 11,357,820

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof; Defendants' Proposed ANDA Products are alleged to be pharmaceutical compositions comprising tirzepatide. ¶76 '820 Patent, col. 1:21-22
NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL; The Proposed ANDA Products are alleged to be formulated with NaCl at a concentration within the claimed range. ¶76 '820 Patent, col. 1:49-50
and dibasic sodium phosphate. The Proposed ANDA Products are alleged to be formulated with dibasic sodium phosphate. ¶76 '820 Patent, col. 2:1-2

Identified Points of Contention

  • Scope Questions: This being a Hatch-Waxman action, the infringement analysis is largely defined by what Defendants' ANDAs specify. For the '780 patent, a core question is whether "tirzepatide" as contained in the Proposed ANDA Products is identical to the compound claimed, including any relevant salt forms. For the '820 patent, a primary question will be whether the proposed generic formulations meet the specific concentration ranges for NaCl and the requirement for "dibasic sodium phosphate."
  • Technical Questions: While direct infringement seems straightforward if the generic copies the branded product, a technical question for the court may be whether different salt forms of tirzepatide or different hydration states of the excipients (e.g., dibasic sodium phosphate) fall within the scope of the claims. The complaint's direct allegation of infringement suggests Plaintiff's position is that they do, but this may become a point of dispute.

V. Key Claim Terms for Construction

Claim Term: "dibasic sodium phosphate" (['820 Patent, claim 1](https://ex:cit:46))

Context and Importance: Practitioners may focus on this term because its precise definition could be outcome-determinative. The claims do not specify a hydration state (e.g., anhydrous, heptahydrate). If Defendants' formulation uses a different hydrate or an anhydrous form of the compound than that described in Lilly's preferred embodiments, the construction of this term will be central to whether the formulation literally infringes.

Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The plain language of claim 1 recites "dibasic sodium phosphate" without any limitation as to its hydration state, which may support a construction covering any form of the chemical '820 Patent, claim 1
  • Evidence for a Narrower Interpretation: The specification's examples and stability studies often refer to specific hydrated forms, such as "Sodium phosphate dibasic 7H2O" '820 Patent, Table 3, p. 10 A defendant may argue this repeated use limits the claim scope to the specific heptahydrate form disclosed in the embodiments.

Claim Term: "a compound of Formula..." (['780 Patent, claim 1](https://ex:cit:48))

Context and Importance: This term defines the active ingredient itself. While infringement appears direct, disputes in chemical compound cases can arise over stereoisomers, polymorphs, or the scope of "pharmaceutically acceptable salt thereof." The validity of this claim, which provides foundational coverage for tirzepatide, will be a central battleground.

Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The claim language "or a pharmaceutically acceptable salt thereof" explicitly broadens the claim beyond the base compound to include various salt forms '780 Patent, claim 1 The specification of a related patent describes "pharmaceutically acceptable salt" as being "well known to the skilled artisan" '820 Patent, col. 3:33-36
  • Evidence for a Narrower Interpretation: The specific structural formula and the sequence listing provided in the patent family define a very precise chemical entity '987 Patent, col. 37:45-53 A defendant may argue that any deviation from this exact structure, beyond a standard salt, falls outside the claim scope. The complaint itself reinforces a narrow focus by providing a precise structural diagram of tirzepatide Compl. ¶59

VI. Other Allegations

Indirect Infringement

The complaint alleges that Defendants will induce infringement by creating a product label that instructs and encourages physicians and patients to use the proposed generic products in an infringing manner, specifically for the patented methods of treating diabetes and obesity with specific dosing regimens Compl. ¶68 Compl. ¶102 Compl. ¶121 Compl. ¶142 Compl. ¶162 Compl. ¶197 Compl. ¶218 The complaint also alleges contributory infringement, stating the products are "especially made or adapted for use in patented methods" and are "not suitable for substantial noninfringing use" Compl. ¶69 Compl. ¶86 Compl. ¶105 Compl. ¶124 Compl. ¶147 Compl. ¶165 Compl. ¶182 Compl. ¶200 Compl. ¶223 Compl. ¶240

Willful Infringement

The complaint does not contain an explicit count for willful infringement, but it lays the factual predicate for such a claim by asserting Defendants had pre-suit knowledge of the asserted patents. This knowledge is alleged to come from the patents' listing in the FDA's Orange Book and Defendants' inclusion of the patents in their notice letters Compl. ¶67 Compl. ¶84 Compl. ¶101 Compl. ¶120 Compl. ¶141 Compl. ¶161 Compl. ¶180 Compl. ¶196 Compl. ¶217 Compl. ¶238

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue for the case will be patent validity. As this is a Hatch-Waxman litigation, the primary defense will likely focus on whether Defendants can prove by clear and convincing evidence that Lilly's patents are invalid for reasons such as obviousness, lack of enablement, or anticipation over prior art not considered by the USPTO.
  • A second key question will be one of claim construction and scope, particularly for the formulation patents. The case may turn on whether terms like "dibasic sodium phosphate" are interpreted broadly to cover various forms or are limited to the specific embodiments disclosed, and how the court construes concentration ranges specified with the word "about."
  • For the method-of-use patents, an evidentiary question will be the interpretation of the proposed label. The court will have to determine whether the instructions on Defendants' proposed ANDA labels will inevitably lead physicians and patients to practice the specific, multi-step dosing and titration regimens recited in claims of patents like the '987 and '740 patents.
Loading Complaint